EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Co-Administration of Fluvoxamine and Morphine: Effects on Nociception and Central Nervous System Function in Healthy Volunteers

Wouter Alexander Bakker, Koen Peter Willem Rietdijk, Roman Bohoslavsky, Karen Broekhuizen, Hemme Jacob Hijma, Albert Dahan, Marieke Niesters, Geert Jan Groeneveld

Pharmaceutics · 15.11.2026 · 18 (11) · 1476

DOI: 10.3390/pharmaceutics18111476 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 15.11.2026. Verfasst von Wouter Alexander Bakker und 7 weiteren Autor:innen. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union, Horizon 2020 European Union grant: QSPainRelief.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Combining opioids with non-opioid analgesics is a potential strategy to improve pain management and reduce opioid requirements, but few such combinations have been systematically characterized in humans. Preclinical studies have shown that the selective serotonin reuptake inhibitor fluvoxamine can potentiate morphine-induced antinociception. We explored the interactive effects of fluvoxamine and morphine on a battery of evoked pain tests, central nervous system (CNS) function (including electroencephalography (EEG)), and adverse effects.

Methods

In a randomized, double-blind, double-dummy, placebo-controlled, four-way crossover study, 24 healthy volunteers received placebo, morphine (3 mg intravenous (IV) at 2 h plus 7 mg IV at 5 h), fluvoxamine (100 mg oral at 0 h), or the combination. Outcomes included responses to evoked pain tests, CNS function tests, and resting-state EEG.

Results

The combination produced greater antinociceptive effects than placebo on cold pressor, electrical-burst, and pressure pain tolerance, but did not significantly enhance pain detection or tolerance thresholds compared with morphine alone. In contrast, the combination significantly reduced capsaicin-induced secondary mechanical allodynia compared with placebo and fluvoxamine monotherapy. These findings were accompanied by distinct reductions in frontal-midline beta- and delta-power on EEG that were not observed with either monotherapy. No significant effects on conditioned pain modulation (CPM) were observed, and additional CNS effects were generally modest.

Conclusions

In conclusion, combination therapy with morphine and fluvoxamine was associated with reduced experimentally induced secondary mechanical allodynia and distinct EEG alterations, without additional effects on pain detection or tolerance thresholds compared with morphine alone.

Förderung

  • European Union
  • Horizon 2020 European Union grant: QSPainRelief

Zitieren

APA

Bakker, W. A., Rietdijk, K. P. W., Bohoslavsky, R., Broekhuizen, K., Hijma, H. J., Dahan, A., Niesters, M., & Groeneveld, G. J. (2026). Co-Administration of Fluvoxamine and Morphine: Effects on Nociception and Central Nervous System Function in Healthy Volunteers. Pharmaceutics, 18(11), 1476. https://doi.org/10.3390/pharmaceutics18111476

Vancouver

Bakker WA, Rietdijk KPW, Bohoslavsky R, Broekhuizen K, Hijma HJ, Dahan A, et al. Co-Administration of Fluvoxamine and Morphine: Effects on Nociception and Central Nervous System Function in Healthy Volunteers. Pharmaceutics. 2026;18(11):1476. doi:10.3390/pharmaceutics18111476

BibTeX
@article{Bakker2026,
  author = {Bakker, Wouter Alexander and Rietdijk, Koen Peter Willem and Bohoslavsky, Roman and Broekhuizen, Karen and Hijma, Hemme Jacob and Dahan, Albert and Niesters, Marieke and Groeneveld, Geert Jan},
  title = {Co-Administration of Fluvoxamine and Morphine: Effects on Nociception and Central Nervous System Function in Healthy Volunteers},
  journal = {Pharmaceutics},
  year = {2026},
  volume = {18},
  number = {11},
  pages = {1476},
  doi = {10.3390/pharmaceutics18111476}
}
Kostenlos starten →